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Pertussis, a serious infectious disease of the respiratory tract caused by Bordetella pertussis, is reemerging in 
vaccinated populations. Efforts to curtail this disease are hampered by limited insight into the basis of protective 
immunity. Opsonophagocytosis was recently found to play a central role in cellular bactericidal activity against 
B. pertussis. In the present study, we studied the specificity of opsonic antibodies. Anti-pertactin antibodies, 
but not anti-pertussis toxin, anti-fimbriae, or anti-filamentous hemagglutinin antibodies, were found to be 
crucial for B. pertussis phagocytosis. These data are consistent with field studies showing that levels of antibodies 
to pertactin correlate with protection.
Pertussis, or whooping cough, is a serious disease of 
the respiratory tract caused by the gram-negative bac­
terium Bordetella pertussis. Despite >40 years of vac­
cination, pertussis is a disease that occurs in endemic 
areas, with epidemic outbreaks occurring every 3-5 
years. Pertussis ranks fifth, after hepatitis B, measles, 
tetanus, and Haemophilus influenzae type b, as a cause 
of global mortality, according to vaccine-preventable 
pediatric infectious diseases [1], In some vaccinated 
populations (e.g., in Australia, Canada, The Nether­
lands, and United States), the incidence of pertussis has 
been increasing over the last decade [2], This is ex­
emplified by the situation in The Netherlands. In 1996, 
the number of reported pertussis cases increased 12- 
fold, compared with the previous year, and, since then, 
the incidence of pertussis has remained high [3], Fur-
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thermore, it has become clear that pertussis is not only 
a childhood disease. Several studies indicated that 12%- 
26% of adults with persistent cough were infected by 
B. pertussis [4], Of importance, pertussis in adults is 
associated with significant morbidity.
Historical data suggest that, initially, the introduction 
of whole cell-pertussis vaccines in the 1950s signifi­
cantly reduced disease burden. Although generally ef­
fective, whole cell vaccines are reactogenic, causing fever 
and local reactions. Concerns about the safety of whole 
cell vaccines led to the development of acellular vac­
cines, composed of 3=1 of the following B. pertussis 
proteins: pertussis toxin (Ptx), filamentous hemagglu­
tinin (FHA), pertactin (Prn), and serotype 2 and 3 
fimbriae (Fim2 and Fim3). Acellular vaccines have now 
been introduced in a number of countries, replacing 
whole cell vaccines. As yet, it is unclear whether acel­
lular vaccines will prove more effective than whole cell 
vaccines in the long run.
Lack of insight into the basis of protective immunity 
against disease and infection has hampered efforts to 
improve pertussis vaccines. Two studies indicated that 
persons with high levels of antibodies to Prn, Fim2, 
Fim3, or Ptx are less likely to develop clinical disease 
when exposed to pertussis [5, 6], However, the mecha­
nism of antibody-mediated protection is poorly un­
derstood. The present study provides a rational basis
Downloaded from https://academ
ic.oup.eom
/jid/article-abstract/188/5/738/851498 by guest on 23 August 2019
738 • JID 2003:188 (1 September) • Hellwig et al.
for the observed correlation between protection against per­
tussis and antibodies to Prn and shows that such antibodies 
are crucial for phagocytosis of B. pertussis by immune cells.
MATERIALS AND METHODS
Bacterial strains. B. pertussis B213 and B1686 are Tohama 
streptomycin-resistant derivatives. Strain B1686 does not pro­
duce pertactin because of a knockout mutation. The strains 
were transformed with plasmid pCW505 [7] (supplied by Dr. 
A. A. Weiss, Cincinnati), which induces cytoplasmic expression 
of green fluorescent protein. Bacteria were stored at — 70°C, 
recovered by growth on Bordet-Gengou agar plates at 35°C for 
3 days, and subsequently recultured overnight on Bordet-Gen­
gou plates before use in phagocytosis experiments.
Serum samples. Serum samples from a study with pertussis 
vaccines in Dutch children aged 4 years [8] were used in this 
study. Children were vaccinated at the ages of 3, 4, 5, and 11 
months with the Dutch whole cell vaccine and were boosted with 
an acellular vaccine consisting of FHA, Ptx, and Prn (Glaxo­
SmithKline) at the age of 4 years. Before and after booster vac­
cination, serum agglutination activity and titers of specific anti­
body to Ptx, FHA, Prn, Fim2, and Fim3 were determined (table 
1). Written informed consent was obtained from a parent, guard­
ian, or adult before enrollment. This study was approved by the 
institutional review board of the National Institute of Public 
Health and the Environment, The Netherlands.
Peripheral blood polymorphonuclear leukocytes (PMNLs). 
Peripheral blood PMNLs were isolated from heparinized venous 
blood of healthy human volunteers (age range, 25-45 years) by 
Histopaque (Sigma-Aldrich) gradient centrifugation. PMNLs 
were harvested, and the remaining erythrocytes were removed 
by hypotonic lysis. Cell viability was >99%, as determined by 
trypan blue exclusion. Before functional assays, PMNLs were 
washed twice with RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal calf serum, resuspended, and used imme­
diately. All experiments described in this study were conducted 
with freshly isolated PMNLs lacking Fey receptor type I expres­
sion, as monitored by cell cytometric analyses with fluorescein 
isothiocyanate-conjugated anti-Fcy receptor type I monoclonal 
antibody 22 [9],
Phagocytosis. Phagocytosis of B. pertussis was evaluated 
as described elsewhere [10], In brief, green fluorescent pro­
tein-expressing B. pertussis were grown overnight on Bordet- 
Gengou agar plates and resuspended in RPMI 1640 medium 
containing 10% fetal calf serum. Bacteria were incubated with 
or without 5% human serum for 30 min at 37°C. After being 
washed, opsonized and nonopsonized bacteria were incubated 
with phagocytic cells in a 70:1 ratio for 45 min at 4°C, to allow
Table 1. Titers of antibodies to pertussis toxin (Ptx), filamentous 
hemagglutinin (FHA), pertactin (Prn), and type 2 and 3 fimbriae 
(Fim2 and Fim3), and agglutinating activity of serum samples from 
donors after booster vaccination.
Donor
Virulence factor
Agglutinating 
activityPtx FHA Prn Fim2 Fim3
1 30 199 33 12 5 4
2 81 66 26 43 9 32
3 8 107 78 57 13 4
4 69 1293 154 23 9 4
5 83 138 120 69 63 8
6 109 2148 156 136 96 128
7 98 232 56 94 12 64
8 24 48 518 45 3 16
9 826 286 88 160 15 2560
10 1411 430 156 212 75 256
11 496 109 517 158 24 64
12 148 981 305 76 17 32
13 1065 2232 454 457 165 256
14 68 222 349 64 10 32
15 3 109 333 240 85.5 512
16 16 607 828 96 5 32
NOTE. Data are antibody titers (ELISA units/mL calculated relative to the 
US reference pertussis antiserum).
for binding of bacteria to PMNLs. After extensive washing to 
remove nonattached bacteria, cells were split into 2 aliquots 
and were further incubated for 30 min at either 4°C or 37°C. 
Next, remaining cell surface-bound opsonized bacteria were 
detected by incubation (30 min at 4°C) with phycoerythrin- 
conjugated goat F(ab')2 of anti-human IgG (Southern Biotech­
nology). After washing, samples were analyzed by flow cyto­
metry. Five thousand cells per sample were analyzed. Green 
and red fluorescence intensities of cells maintained at 4°C 
throughout served as controls for bacterial binding (i.e., no 
phagocytosis). The decrease in red fluorescence of green-posi­
tive cells after incubation at 37°C reflects bacterial phagocytosis, 
as confirmed microscopically [10]. Phagocytosis rates were cal­
culated from the drop in mean red fluorescence intensity of 
green-positive cells, as described elsewhere [10],
ELISA and bacterial agglutination. Titers of antibodies 
to Ptx, FHA, Prn, Fim2, and Fim3 were determined by 
ELISA, as described elsewhere [11], In brief, 96-well plates 
were coated with purified Ptx, FHA, Fim2, Fim3 (National 
Institute of Health and the Environment), or Prn (Chiron) 
at a concentration of 1, 2, 3, 3, and 3 yig/mL, respectively. 
For each serum, eight 2-fold dilutions were tested starting 
with a 1:60 dilution. Bound IgG was detected after 2 h of 
incubation (room temperature) with alkaline phosphatase-
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Figure 1. Effect of serum samples collected before and after booster vaccination on phagocytosis by human polymorphonuclear leukocytes (PMNLs). 
A. Bordetella pertussis were opsonized with human sera (5%) obtained before (Pre sera) or after (Post sera) booster vaccination with a 3-component 
acellular vaccine consisting of filamentous hemagglutinin, pertussis toxin, and pertactln. Phagocytosis by freshly Isolated human PMNLs was expressed 
In arbitrary units (AU). Data from 1 experiment of 3 are shown. B, Correlation between B. pertussis phagocytosis and anti—pertactln antibody titers 
In serum samples obtained after booster vaccination. Serum nos. In figure correspond with serum nos. In table 1.
conjugated goat anti-human IgG (Sigma; working dilution, 
30,000).
ELISA units (EU) were calculated relative to the US reference 
pertussis antiserum (human; obtained from the US Food and 
Drug Administration), lot 3 for Ptx, FHA, and Fim and lot 4 
for Prn, by use of the 4-parameter III method in KC4 (Kineticalc 
for Windows) with a BioTek plate reader (EL312e; BioTek). The 
minimum level of detection was estimated to be 2 EU/mL for 
anti-Ptx and anti-FHA antibodies, 4 EU/mL for anti-Prn anti­
bodies, 2 EU/mL for anti-Fim2 antibodies, and 1 EU/mL for 
anti-Fim3 antibodies.
Agglutinating antibodies were measured essentially as de­
scribed elsewhere [12], with use of B. pertussis 3838 as antigen. 
US pertussis antiserum was used as reference, and a control 
serum was included on each plate. For each serum, a 2-fold 
dilution series in 8 wells was tested (starting with a 1:4 dilu­
tion). The agglutination titer is expressed as the reciprocal of 
the highest final dilution of serum resulting in agglutination.
Statistical analysis. Antibody titers were converted to log,,, 
values before analyses for linear correlation. Pearson’s product 
moment correlation coefficient [13] was calculated for phago­
cytosis rates and the inverse of log-converted titers of antibody 
to selected bacterial antigens. Student’s t test was used to assess 
the significance of differences between phagocytosis rates induced 
by the different sera. Significance was accepted at P< .05.
RESULTS
B. pertussis containing pCW505, a plasmid coding for the green 
fluorescent protein, was incubated with serum specimens from 
16 children obtained before and after booster vaccination with 
acellular vaccine. Subsequently, bacteria were incubated with hu­
man PMNLs, and phagocytosis was quantided by how cytometry. 
Thirteen of the 16 postvaccination serum samples enhanced 
phagocytosis. In contrast, no phagocytic effect was observed and 
no antibodies were detected by ELISA or agglutination in any 
of the 16 serum samples obtained before booster vaccination 
(figure 1A). A statistically significant correlation was found be­
tween phagocytosis and titers of antibody to Prn (BFrn = 0.71 
and PPln = .001; figure IB), whereas correlations with aggluti­
nation titers (B;gg = O.Oland Pagg = .9) or titers of antibody to 
Ptx, FHA, Fim2, and Fim3 were not significant (respectively, 
Bptx = 0.32 and Pptx = .13; BFHA = 0.03 and PFHA = .17; 
^Hn,2 = 0.2 and PFim2 = .09; and BFim3 = 0.05 and PFim3 = .4).
To further investigate the role of antibodies to Prn in in­
ducing phagocytosis, 3 serum samples with different levels of 
anti-pertactin antibodies (donors 9, 13, and 16) were depleted 
of antibodies to Prn, Fim2, or Fim3 by incubation with the 
respective purified proteins. Purity of Prn and Fim antigens 
used for depletion was confirmed by SDS-PAGE and immuno­
blot analyses. After depletion of antibodies to Prn, the ability 
of the serum to induce phagocytosis was nearly absent, whereas 
depletion of antibodies to Fim2 and Fim3 had no such effect 
(figure 2A). Of importance, although a drastic decrease in anti- 
Prn antibody titer was observed after incubation with purified 
Prn, neither titers of antibodies to the other antigens (Ptx, FHA, 
Fim2, and Fim3) nor serum agglutinating activity were affected 
(data not shown). Similarly, incubation of serum samples with 
Fim2 and Fim3 antigens solely depleted anti-Fim2 and 
anti-Fim3 antibodies from serum, as determined by ELISA. 
Finally, serum samples that were potent in facilitating phago­
cytosis exhibited a strongly reduced ability to induce phago­
cytosis of a B. pertussis strain defective in Prn expression (figure 
2B). In combination, these data show Prn to represent an im­
portant target for antibody-mediated phagocytosis.
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Figure 2. Antibodies to pertactin are crucial for phagocytosis. A, Serum samples collected after booster vaccination (Post sera) were either depleted 
of antibodies directed against serotype 2 and 3 fimbriae (Firn) or pertactin (Prn) by overnight incubation with saline (Control serum) or the respective 
purified proteins. Subsequently, Bordetella pertussis was Incubated with and without the respective serum sample, and phagocytosis was quantified. 
Phagocytosis induced by control serum was set at 100%. ^Phagocytosis induced in the absence of serum, or by anti—Prn antibody-depleted serum, 
was statistically different from phagocytosis Induced by control serum or anti—Flm antibody-depleted serum (P< .05; 2-slded Student's t test). B, 
Wild-type B. pertussis (Bp) and a B. pertussis mutant without Prn expression (Bp Prn-) were opsonized with postvaccination serum (serum 12 and 
serum 16), and phagocytosis was quantified. Phagocytosis of the wild-type strains was arbitrarily set at 100%. *P< .05, between phagocytosis values 
of opsonized wild-type B. pertussis strain and opsonized B. pertussis Prn- mutant strain. Data are mean ± SD of 3 Independent experiments.
DISCUSSION
Previous studies have indicated that antibodies to Prn are im­
portant for protection against disease. Field trials revealed clin­
ical protection to correlate with levels of anti-Prn antibodies 
[5, 6], Furthermore, 3-component acellular vaccines containing 
FHA, Ptx, and Prn were shown to be significantly more effi­
cacious than 2-component vaccines with solely FHA and Ptx 
in the same study (vaccine efficacies of 84% vs. 59%) [14], Prn 
is one of the few B. pertussis proteins that exhibit antigenic 
variation [ 15], and antigenic divergence between vaccine strains 
and clinical isolates has been observed in a number of vacci­
nated populations, which suggests a significant effect of anti- 
Prn antibodies on strain transmission [16-19], By use of a 
mouse model, it was shown that the variable region of Prn 
harbors a protective epitope and that a whole cell vaccine was 
less effective against strains producing nonvaccine-type Prn 
variants [20], Phagocytosis and subsequent killing of micro­
organisms represents a potent immune mechanism for clearing 
bacteria from the respiratory tracts of infected persons. We have 
recently demonstrated that antibody-mediated phagocytosis is 
a key mechanism for B. pertussis killing by phagocytes [9, 21], 
By using a flow cytometry-based phagocytosis assay that allows
accurate assessment of B. pertussis phagocytosis, we could de­
termine that, in the absence of opsonic antibodies, binding of 
B. pertussis to phagocytes is drastically reduced. Under these 
conditions, neither bacterial phagocytosis nor cellular bacte­
ricidal effector functions against this pathogen takes place. In 
the present study, anti-Prn antibodies, but not anti-Ptx, 
anti-Fim2, anti-Fim3, or anti-FHA antibodies, were shown to 
be crucial for B. pertussis phagocytosis. These data provide a 
biological basis for the well-documented, but poorly under­
stood, observation of a close correlation between antibodies to 
Prn and protection. In contrast to anti-FHA antibodies, anti­
bodies to Ptx, Fim2, and Fim3 also were found to correlate 
with protection in humans [5, 6], Although we found no evi­
dence for involvement of antibodies to Ptx, Fim2, and Fim3 
in phagocytosis, these antibodies may well confer protection 
by other mechanisms, such as complement-mediated killing, 
blocking of bacterial adherence, and antitoxin activity. Prn is 
the only antigen present in acellular vaccine that induces op­
sonic antibodies. Prn variants have been documented in a num­
ber of populations over the years and are presently causing 
outbreaks [15-19], This study provides a new view on the 
importance of Prn as a vaccine candidate despite the traditional 
view of this antigen as a mere adhesin to be blocked. Moreover,
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it provides new and relevant evidence that sheds some light on 
the problem of B. pertussis persistence within the population.
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